Abacavir/dolutegravir/lamivudine
| Combination of | |
|---|---|
| Abacavir | reverse transcriptase inhibitor |
| Dolutegravir | integrase inhibitor |
| Lamivudine | nucleoside analog reverse transcriptase inhibitor |
| Clinical data | |
| Identifiers | |
Abacavir/dolutegravir/lamivudine (trade name Triumeq) is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of three drugs with different and complementary mechanisms of action: abacavir, a reverse transcriptase inhibitor, dolutegravir an integrase inhibitor, and lamivudine, a nucleoside analog reverse transcriptase inhibitor.
The drug was developed by ViiV Healthcare and approved by the Food and Drug Administration for use in the United States in August 2014.[1]
See Also
- Abacavir/lamivudine - tradename Kivexa or Epzicom
- Abacavir/lamivudine/zidovudine - tradename Trizivir
References
- ↑ "FDA Approves Triumeq". drugs.com. August 22, 2014.